Quantcast

Latest Cystic fibrosis Stories

2014-07-28 20:24:33

HAYWARD, Calif., July 28, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014. Net loss for the three months ended June 30, 2014 was $7.3 million, compared to $8.3 million for the same period in 2013. The decrease in net loss is a direct result of a decrease in interest expense in the current period. Net loss for the six months ended June 30, 2014 was $15.2 million,...

2014-07-25 10:36:51

UNC The study, led by Martina Gentzsch, PhD, provides evidence that could help drug developers improve compounds aimed at correcting CFTR proteins in cystic fibrosis patients. In lab experiments using tissue samples cultured from cystic fibrosis patients, scientists at the UNC School of Medicine and the UNC Marsico Lung Institute have shown that a new CF drug counteracts the intended beneficial molecular effect of another CF drug. The finding, published today in the journal Science...

2014-07-24 23:12:56

80s cover band Flashback Heart Attack topped last year's performance at the Cystic Fibrosis Foundation annual charity event by breaking out the rock stars Saturday night. The night set record numbers on attendance and net a profit for Pipeline to a Cure and the Cystic Fibrosis Foundation. Huntington Beach, CA (PRWEB) July 24, 2014 The event, called Pipeline to a Cure, took place Saturday July 19, 2014 at the Hyatt Regency in Huntington Beach, Calif. The evening, coming off the buzz...

2014-07-16 23:04:17

ReportsnReports.com adds “OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 – Event-Driven Update” to its store. The majority of Cystic Fibrosis sales will come from the US, which will represent 60% of the market by 2018. Dallas, TX (PRWEB) July 16, 2014 Researcher estimates the 2012 sales for Cystic Fibrosis to be approximately $1.2 billion across the six markets covered in this forecast: the US, France, Germany, Italy, Spain and the UK. By the end...

2014-07-14 16:24:30

Anthera to Form a New Subsidiary, Alkira Therapeutics, to Assume All Development Activities and Registration Activities as a Subsidiary of Anthera HAYWARD, Calif., July 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT") from Eli Lilly and Company. Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment...

2014-07-09 23:13:42

Los Angeles teen, Claire Wineland, receives prestigious award for her foundation’s dedication to making a difference in the lives of others living with cystic fibrosis. Los Angeles, CA (PRWEB) July 09, 2014 Claire’s Place Foundation, a nonprofit organization founded by 17-year-old Claire Wineland, was awarded “Small Nonprofit Organization of the Year” by the Los Angeles Business Journal for their work helping children and families affected by cystic fibrosis. On June 25th the Los...

2014-06-30 08:30:32

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein. The Phase 3 confirmatory trial is...

2014-06-24 12:27:59

CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process BETHESDA, Md., June 24, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation applauds the successful results of Phase 3 studies of ivacaftor (Kalydeco(TM)) in combination with lumacaftor (VX-809) for people with two copies of the F508del mutation of cystic fibrosis (CF). The results showed significant improvements in lung function and other key measures of the disease,...

2014-06-18 12:36:05

NEW YORK, June 18, 2014 /PRNewswire-iReach/ -- DKBmed, LLC has launched a newly designed website that facilitates greater access to the company's successful continuing medical education programs for learners, partners and supporters. The programs are designed to close knowledge and practice gaps among healthcare practitioners through e-mail and Internet programs, mobile technology, and live presentations. The website is accessible at www.dkbmed.com. (Photo:...

2014-06-17 16:25:49

DUBLIN, June 17, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/pt3c6f/nebulizers_market) has announced the addition of the "Global Nebulizers (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) Market - Forecasts to 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769A nebulizer is a medical device used for the treatment of respiratory disorders (asthma, COPD and cystic fibrosis) that converts liquid...


Latest Cystic fibrosis Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »
Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'